Is This Diabetes Drug Stock in Jeopardy?

The news that pharmacy-benefits manager Express Scripts is ditching the world's biggest diabetes-focused company came as a surprise. It will no longer use Novo Nordisk's Victoza, or any of its diabetes products, including insulin. The implications are threefold.

This is a clear blow for Novo Nordisk, as it will negatively affect sales of not only Victoza but also Novolog, and it may be hard for Novo to hit earnings guidance. It's also interesting that Express Scripts would go with a less premium product than Victoza -- it's an indication that it may be using its post-merger weight to negotiate better deals for branded products, given Victoza's popularity. Finally, this is a clear win for Eli Lilly, and it validates management's decision to become a diabetes powerhouse, even if a lot of its offerings are still in drug development.

In this video, health-care analyst David Williamson discusses what these events mean for investors in Novo Nordisk, Eli Lilly, and Express Scripts, along with the broader implications of this decision. 

One of the best parts of owning Big Pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.

Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 14, 2013, at 6:46 PM, peachykean wrote:

    David - Need your help. When was this info on Novo Nordisk products announced by ExpressScripts? Who in their organization made this announcement (or announcements) and when?

    Please advise as I need to reach out to them.

    Thank you.

  • Report this Comment On September 18, 2013, at 7:45 AM, kthornt wrote:

    This guy doesn't know what he's talking about and needs to learn how to pronounce these products

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2637826, ~/Articles/ArticleHandler.aspx, 9/29/2016 10:06:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 50 minutes ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:05 PM
BMY $53.87 Down -1.22 -2.21%
Bristol-Myers Squi… CAPS Rating: ****
ESRX $69.84 Down -1.09 -1.54%
Express Scripts CAPS Rating: *****
LLY $79.74 Down -0.97 -1.20%
Eli Lilly and Co. CAPS Rating: ***
MRK $61.91 Down -1.39 -2.20%
Merck and Co. CAPS Rating: ****
NVO $41.80 Down -1.94 -4.44%
Novo Nordisk CAPS Rating: *****